Dermatitis atópica, Dra Liliana Guevara. 13 de septiembre 2018

De




Dermatitis atópica 
Dra Liliana Guevara. 
2018

Comentarios

  1. Liliana Guevara14 de septiembre de 2018 a las 8:49

    Conclusiones:

    1. La dermatitis atópica es una enfermedad heterogénea.

    2. Los cuidados básicos de la piel es la estrategia terapéutica más importante.

    3. El advenimiento de terapias biológicas con blancos terapéuticos dirigidos, podría modificar la historia natural de la enfermedad.

    4. Recientes estudios han identificado un aumento en el riesgo de desarrollar malignidades de tipo linfoma, con el uso prolongado de inhibidores de la calcineurina.

    ResponderEliminar
  2. Ricardo Cardona Villa17 de septiembre de 2018 a las 14:00

    Artículo recomendado:

    Atopic dermatitis
    Stephan Weidinger1*, Lisa A. Beck2, Thomas Bieber3,4, Kenji Kabashima5
    and Alan D. Irvine6,7,8*

    Abstract

    Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life. AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course. AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as
    asthma and allergic rhinitis). Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations. Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration.
    The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption. Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune
    responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch. Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific
    3ʹ,5ʹ-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants. Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.

    Texto completo:
    https://doi.org/10.1038/s41572-018-0001-z

    ResponderEliminar

Publicar un comentario

Entradas populares de este blog

Future perspectives of anticholinergics for the treatment of asthma in adults and children. Viernes 4 de octubre

De
Future perspectives of anticholinergics for the treatment of asthma in adults and children. Authors : Buhl R1, Hamelmann E2,3. 1 Pulmonary Department, Johannes Gutenberg University Hospital Mainz, Mainz, Germany, roland.buhl@unimedizin-mainz.de. 2 Children's Center Bethel, Evangelic Hospital Bethel, Department of Pediatrics, Bielefeld, Germany. 3 University Children's Hospital, Allergy Center Ruhr, Ruhr University Bochum, Bochum, Germany. Abstract Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-ac...
Leer más

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

De
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat...
Leer más

2019 ARIA Care pathways for allergen immunotherapy. Fecha: Martes 28 de mayo

De
2019 ARIA Care pathways for allergen immunotherapy. Authors:  Bousquet J1,2, Pfaar O3, Togias A4, Schünemann HJ5, Ansotegui I6, Papadopoulos NG7, Tsiligianni I8, Agache I9, Anto JM10,11,12,13, Bachert C14, Bedbrook A1, Bergmann KC15, Bosnic-Anticevich S16, Bosse I17, Brozek J5, Calderon M18, Canonica GW19, Caraballo L20, Cardona V21, Casale T22, Cecchi L23, Chu DK5, Costa E24, Cruz AA25, Czarlewski W26, Durham SR27, Du Toit G26, Dykewicz M28, Ebisawa M29, Fauquert JL30, Fernandez-Rivas M31, Fokkens WJ32, Fonseca J33, Fontaine JF34, van Wijk RG35, Haahtela T36, Halken S37, Hellings PW38, Ierodiakonou D8, Iinuma T39, Ivancevich JC40, Jacobsen L41, Jutel M42, Kaidashev I43, Khaitov M44, Kalayci O45, Kleine Tebbe J46, Klimek L46, Kowalski ML47, Kuna P48, Kvedariene V49, La Grutta S50, Larenas-Linemann D51, Lau S52, Laune D53, Le L54, Carlsen KL55, Lourenço O56, Malling HJ57, Marien G58, Menditto E59, Mercier G60, Mullol J61, Muraro A62, O'Hehir R63, Okamoto Y39, Pajno GB64, Park...
Leer más